Ignite Creation Date:
2025-12-24 @ 5:50 PM
Ignite Modification Date:
2025-12-28 @ 9:48 AM
Study NCT ID:
NCT06340568
Status:
RECRUITING
Last Update Posted:
2025-12-15
First Post:
2024-03-25
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D016889', 'term': 'Endometrial Neoplasms'}], 'ancestors': [{'id': 'D014594', 'term': 'Uterine Neoplasms'}, {'id': 'D005833', 'term': 'Genital Neoplasms, Female'}, {'id': 'D014565', 'term': 'Urogenital Neoplasms'}, {'id': 'D009371', 'term': 'Neoplasms by Site'}, {'id': 'D009369', 'term': 'Neoplasms'}, {'id': 'D014591', 'term': 'Uterine Diseases'}, {'id': 'D005831', 'term': 'Genital Diseases, Female'}, {'id': 'D052776', 'term': 'Female Urogenital Diseases'}, {'id': 'D005261', 'term': 'Female Urogenital Diseases and Pregnancy Complications'}, {'id': 'D000091642', 'term': 'Urogenital Diseases'}, {'id': 'D000091662', 'term': 'Genital Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D004317', 'term': 'Doxorubicin'}, {'id': 'D017239', 'term': 'Paclitaxel'}], 'ancestors': [{'id': 'D003630', 'term': 'Daunorubicin'}, {'id': 'D018943', 'term': 'Anthracyclines'}, {'id': 'D009279', 'term': 'Naphthacenes'}, {'id': 'D011084', 'term': 'Polycyclic Aromatic Hydrocarbons'}, {'id': 'D006841', 'term': 'Hydrocarbons, Aromatic'}, {'id': 'D006844', 'term': 'Hydrocarbons, Cyclic'}, {'id': 'D006838', 'term': 'Hydrocarbons'}, {'id': 'D009930', 'term': 'Organic Chemicals'}, {'id': 'D011083', 'term': 'Polycyclic Compounds'}, {'id': 'D000617', 'term': 'Aminoglycosides'}, {'id': 'D006027', 'term': 'Glycosides'}, {'id': 'D002241', 'term': 'Carbohydrates'}, {'id': 'D043823', 'term': 'Taxoids'}, {'id': 'D043822', 'term': 'Cyclodecanes'}, {'id': 'D003516', 'term': 'Cycloparaffins'}, {'id': 'D006840', 'term': 'Hydrocarbons, Alicyclic'}, {'id': 'D004224', 'term': 'Diterpenes'}, {'id': 'D013729', 'term': 'Terpenes'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE3'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ESTIMATED', 'count': 504}}, 'statusModule': {'overallStatus': 'RECRUITING', 'startDateStruct': {'date': '2025-06-10', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2025-12', 'completionDateStruct': {'date': '2029-11', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2025-12-10', 'studyFirstSubmitDate': '2024-03-25', 'studyFirstSubmitQcDate': '2024-03-25', 'lastUpdatePostDateStruct': {'date': '2025-12-15', 'type': 'ESTIMATED'}, 'studyFirstPostDateStruct': {'date': '2024-04-01', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2028-03', 'type': 'ESTIMATED'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'PFS assessed by BICR in the endometrial cancer population in participants with prior ICI treatment', 'timeFrame': 'Up to approximately 32 months', 'description': 'Defined as the time from randomization to the first objective tumor progression (per RECIST 1.1) or death from any cause, whichever occurs first.'}], 'secondaryOutcomes': [{'measure': 'PFS assessed by BICR in the endometrial cancer population in all participants with HER2-expressing recurrent endometrial cancer', 'timeFrame': 'Up to approximately 32 months', 'description': 'Defined as the time from randomization to the first objective tumor progression (per RECIST 1.1) or death from any cause, whichever occurs first'}, {'measure': 'Overall survival (OS) in the endometrial cancer population in participants with prior ICI treatment and in all participants', 'timeFrame': 'Up to approximately 55 months', 'description': 'Defined as the time from randomization to death from any cause.'}, {'measure': 'PFS assessed by the investigator in the endometrial cancer population in participants with prior ICI treatment and in all participants', 'timeFrame': 'Up to approximately 32 months', 'description': 'Defined as the time from randomization to the first objective tumor progression (per RECIST 1.1) or death from any cause, whichever occurs first.'}, {'measure': 'Objective response rate (ORR) assessed by BICR in the endometrial cancer population in participants with prior ICI treatment and in all participants', 'timeFrame': 'Up to approximately 55 months', 'description': 'Defined as the proportion of participants in whom a complete response (CR) or partial response (PR) (per RECIST 1.1) is observed as best overall response with confirmation.'}, {'measure': 'ORR assessed by the investigator in the endometrial cancer population in participants with prior ICI treatment and in all participants', 'timeFrame': 'Up to approximately 55 months', 'description': 'Defined as the proportion of participants in whom a complete response (CR) or partial response (PR) (per RECIST 1.1) is observed as best overall response with confirmation.'}, {'measure': 'Duration of response (DoR) assessed by BICR in the endometrial cancer population in participants with prior ICI treatment and in all participants', 'timeFrame': 'Up to approximately 55 months', 'description': 'Defined as the time from first objective response (CR or PR per RECIST 1.1) to first occurrence of objective tumor progression (PD per RECIST 1.1) or death from any cause, whichever occurs first.'}, {'measure': 'DoR assessed by the investigator in the endometrial cancer population in participants with prior ICI treatment and in all participants', 'timeFrame': 'Up to approximately 55 months', 'description': 'Defined as the time from first objective response (CR or PR per RECIST 1.1) to first occurrence of objective tumor progression (PD per RECIST 1.1) or death from any cause, whichever occurs first.'}, {'measure': 'Percentage of participants with occurrence of treatment-emergent adverse events (TEAEs)', 'timeFrame': 'Up to 35 days after the last dose of study treatment', 'description': 'TEAEs including Grade ≥3, serious, and fatal TEAEs by relationship.'}, {'measure': 'Percentage of participants with occurrence of TEAEs leading to drug interruption, dose reduction, or discontinuation of study treatment.', 'timeFrame': 'Up to 35 days after the last dose of study treatment'}]}, 'oversightModule': {'oversightHasDmc': True, 'isFdaRegulatedDrug': True, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'keywords': ['Human epidermal growth factor receptor 2 (HER2)', 'HER2-expressing tumors', 'Recurrent endometrial cancer', 'IHC scores 1+, 2+, and 3+', 'Immune checkpoint inhibitor', 'Platinum-based therapy', 'HER2 protein expression', 'HER2-expressing endometrial cancer', 'ErbB-2 receptor', 'Antibody drug conjugate (ADC)'], 'conditions': ['Endometrial Cancer']}, 'referencesModule': {'references': [{'pmid': '40966692', 'type': 'DERIVED', 'citation': 'Secord AA, Powell MA, McAlpine J. Molecular Characterization and Clinical Implications of Endometrial Cancer. Obstet Gynecol. 2025 Nov 1;146(5):660-671. doi: 10.1097/AOG.0000000000006080. Epub 2025 Sep 18.'}]}, 'descriptionModule': {'briefSummary': "The goal of this clinical study is to assess the efficacy of BNT323/DB-1303 compared with investigator's choice of chemotherapy in terms of progression-free survival (PFS) by blinded independent central review (BICR) in the endometrial cancer population with prior immune checkpoint inhibitor (ICI) treatment.", 'detailedDescription': "This is an open-label, randomized, multi-site, Phase III, interventional clinical study designed to determine the efficacy and safety of BNT323/DB-1303 compared with investigator's choice of single agent chemotherapy in previously treated participants with recurrent endometrial cancer, whose disease has progressed on at least one line of platinum-based therapy.\n\nParticipants will be randomized 2:1 to receive either BNT323/DB-1303 or investigator's choice of single agent chemotherapy (doxorubicin or paclitaxel) until Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) defined progressive disease (PD) unless there is unacceptable toxicity, withdrawal of consent, or another criterion for discontinuation is met. Randomization will be stratified by HER2 expression (immunohistochemistry score 1+ vs 2+ vs 3+), number of prior lines of therapy (1 vs 2+), and prior ICI treatment (yes vs no).\n\nThe study consists of a two-part screening period (Part 1 \\[tissue screening\\] and Part 2 \\[screening\\]) a treatment period, a safety follow-up period, an efficacy follow-up period, and a long-term survival follow-up. The expected treatment duration per participant is \\~6 months, followed by an anticipated long-term survival follow-up period of up to 55 months."}, 'eligibilityModule': {'sex': 'FEMALE', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': "Key Inclusion Criteria:\n\n* Are female adults (defined as ≥18 years of age or acceptable age according to local regulations at the time of voluntarily giving informed consent).\n* Have histologically confirmed endometrial cancer that:\n\n * Is recurrent,\n * Has a HER2 IHC score of 1+, 2+, or 3+ as determined by central laboratory testing for HER2 protein expression, and\n * Is not defined as a true sarcoma (i.e., leiomyosarcoma or endometrial stromal sarcoma). Note: Uterine carcinosarcoma is allowed.\n* Have measurable disease defined by RECIST 1.1.\n* Have Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1 or 2.\n* Have had at least one prior line of platinum-based therapy (in any setting). Up to three lines of prior therapy are allowed. Prior hormonal therapy and radiation are allowed and do not count as prior lines of therapy. Platinum-based chemotherapy and ICI may have been given together or in separate lines of therapy.\n* Have a life expectancy of ≥12 weeks at screening.\n\nKey Exclusion Criteria:\n\n* Ineligible for all options in the investigator's choice of chemotherapy arm. Participants with contraindications to paclitaxel and doxorubicin treatment, per local prescribing information and institutional guidelines, cannot be enrolled to the study.\n* Have a history of small bowel obstruction requiring hospitalization within the past 3 months prior to randomization.\n* Have an uncontrolled intercurrent illness that would limit compliance with study requirement or substantially increase risk of incurring adverse events (AEs).\n* Have clinically uncontrolled pleural effusion, ascites or pericardial effusion requiring drainage, peritoneal shunt, or cell-free concentrated ascites reinfusion therapy within 2 weeks prior to randomization.\n* Have a history of (non-infectious) interstitial lung disease (ILD)/pneumonitis that required steroids, have current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at screening.\n* Participants with prior use of immunosuppressive medication within 14 days prior to first dose of study treatment, except for intranasal and inhaled corticosteroids or systemic corticosteroids at doses of less than 10 mg/day of prednisone or equivalent, and topical corticosteroids. Participants receiving corticosteroids may continue if the dose is stable upon giving informed consent.\n* Have a lung-specific intercurrent clinically significant illness including, but not limited to, any underlying pulmonary disorder (e.g., pulmonary emboli within 3 months prior to study randomization, severe asthma, severe chronic obstructive pulmonary disorder, restrictive lung disease, pulmonary fibrosis, radiation pneumonitis, significant pleural effusion etc.), and any autoimmune, connective tissue or inflammatory disorder with pulmonary involvement (i.e., rheumatoid arthritis, Sjogren's syndrome, sarcoidosis etc.), and/or prior pneumonectomy (complete).\n* Have uncontrolled infection requiring systemic antibiotics, antivirals, or antifungals within 2 weeks prior to randomization.\n* Have unresolved toxicities from previous anti-cancer therapy, defined as toxicities (other than alopecia) not yet resolved to Grade ≤1 or baseline.\n* Are pregnant or breastfeeding or are planning pregnancy during the study or within 7 months after the last dose of study treatment.\n* Have a history of allergies, hypersensitivities, or intolerance to the study treatments (investigational medicinal products and auxiliary medicinal product) including any excipients thereof or to other monoclonal antibodies.\n* Had prior treatment with topoisomerase I inhibitors, including ADCs with exatecans.\n* Have left ventricular ejection fraction (LVEF) \\<55% by either echocardiography (ECHO) or multiple-gated acquisition (MUGA) within 28 days before randomization. This includes participants with tissue doppler E/e' ratio \\>15.\n\nNOTE: Other protocol defined Inclusion/Exclusion criteria may apply."}, 'identificationModule': {'nctId': 'NCT06340568', 'acronym': 'Fern-EC-01', 'briefTitle': 'A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer', 'organization': {'class': 'INDUSTRY', 'fullName': 'BioNTech SE'}, 'officialTitle': "A Phase III, Randomized, Multi-site, Open-label Trial of BNT323/DB-1303 Versus Investigator's Choice of Chemotherapy in Previously Treated Patients With HER2- Expressing Recurrent Endometrial Cancer", 'orgStudyIdInfo': {'id': 'BNT323-01'}, 'secondaryIdInfos': [{'id': 'GOG-3105', 'type': 'OTHER', 'domain': 'GOG foundation'}, {'id': '2023-507525-42-00', 'type': 'CTIS'}, {'id': 'ENGOT- en25/NSGO-CTU', 'type': 'OTHER', 'domain': 'European Network for Gynaecological Oncological Trial groups (ENGOT)'}]}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'BNT323/DB-1303', 'interventionNames': ['Drug: BNT323/DB-1303']}, {'type': 'ACTIVE_COMPARATOR', 'label': 'Doxorubicin or paclitaxel', 'description': "Single agent chemotherapy (either doxorubicin or paclitaxel) per investigator's choice", 'interventionNames': ['Drug: Doxorubicin', 'Drug: Paclitaxel']}], 'interventions': [{'name': 'BNT323/DB-1303', 'type': 'DRUG', 'otherNames': ['trastuzumab pamirtecan'], 'description': 'intravenous (IV) infusion', 'armGroupLabels': ['BNT323/DB-1303']}, {'name': 'Doxorubicin', 'type': 'DRUG', 'description': 'IV bolus or infusion', 'armGroupLabels': ['Doxorubicin or paclitaxel']}, {'name': 'Paclitaxel', 'type': 'DRUG', 'description': 'IV infusion', 'armGroupLabels': ['Doxorubicin or paclitaxel']}]}, 'contactsLocationsModule': {'locations': [{'zip': 'F5300COE', 'city': 'La Rioja', 'status': 'RECRUITING', 'country': 'Argentina', 'facility': 'Investigaciones CORI S.R.L.', 'geoPoint': {'lat': -29.41328, 'lon': -66.85637}}, {'zip': '5000', 'city': 'Adelaide', 'status': 'RECRUITING', 'country': 'Australia', 'facility': 'Cancer Research SA', 'geoPoint': {'lat': -34.92866, 'lon': 138.59863}}, {'zip': '2250', 'city': 'Gosford', 'status': 'RECRUITING', 'country': 'Australia', 'facility': 'Gosford Hospital', 'geoPoint': {'lat': -33.4244, 'lon': 151.34399}}, {'zip': '3021', 'city': 'Saint Albans', 'status': 'RECRUITING', 'country': 'Australia', 'facility': 'Sunshine Hospital', 'geoPoint': {'lat': -37.73333, 'lon': 144.8}}, {'zip': '4001', 'city': 'South Brisbane', 'status': 'RECRUITING', 'country': 'Australia', 'facility': 'Mater Hospital Brisbane', 'geoPoint': {'lat': -27.48034, 'lon': 153.02049}}, {'zip': '2500', 'city': 'Wollongong', 'status': 'RECRUITING', 'country': 'Australia', 'facility': 'Wollongong Hospital', 'geoPoint': {'lat': -34.424, 'lon': 150.89345}}, {'zip': 'H3T 1E2', 'city': 'Montreal', 'status': 'RECRUITING', 'country': 'Canada', 'facility': 'Jewish General Hospital', 'geoPoint': {'lat': 45.50884, 'lon': -73.58781}}, {'zip': 'A1V 3V6', 'city': "St. John's", 'status': 'RECRUITING', 'country': 'Canada', 'facility': 'Health Sciences Centre', 'geoPoint': {'lat': 47.56494, 'lon': -52.70931}}, {'zip': 'M5G 2M9', 'city': 'Toronto', 'status': 'RECRUITING', 'country': 'Canada', 'facility': 'Princess Margaret Cancer C', 'geoPoint': {'lat': 43.70643, 'lon': -79.39864}}, {'zip': '400010', 'city': 'Chongqing', 'state': 'Chongqing Municipality', 'status': 'RECRUITING', 'country': 'China', 'facility': 'The Second Affiliated Hospital of Chongqing Medical University', 'geoPoint': {'lat': 29.56026, 'lon': 106.55771}}, {'zip': '730050', 'city': 'Lanzhou', 'state': 'Gansu', 'status': 'RECRUITING', 'country': 'China', 'facility': 'Gansu Provincial Maternity and Child-care Hospital', 'geoPoint': {'lat': 36.05701, 'lon': 103.83987}}, {'zip': '515063', 'city': 'Shantou', 'state': 'Guangdong', 'status': 'RECRUITING', 'country': 'China', 'facility': 'Cancer Hospital of Shantou University Medical College', 'geoPoint': {'lat': 23.35489, 'lon': 116.67876}}, {'zip': '530200', 'city': 'Nanning', 'state': 'Guangxi', 'status': 'RECRUITING', 'country': 'China', 'facility': 'Guangxi Medical University Affiliated Tumor Hospital', 'geoPoint': {'lat': 22.81667, 'lon': 108.31667}}, {'zip': '150091', 'city': 'Harbin', 'state': 'Heilongjiang', 'status': 'RECRUITING', 'country': 'China', 'facility': 'Harbin Medical University Cancer Hospital', 'geoPoint': {'lat': 45.75, 'lon': 126.65}}, {'zip': '450014', 'city': 'Zhengzhou', 'state': 'Henan', 'status': 'RECRUITING', 'country': 'China', 'facility': 'The Second Affiliated Hospital of Zhengzhou University', 'geoPoint': {'lat': 34.75778, 'lon': 113.64861}}, {'zip': '430079', 'city': 'Wuhan', 'state': 'Hubei', 'status': 'RECRUITING', 'country': 'China', 'facility': 'Hubei Cancer Hospital', 'geoPoint': {'lat': 30.58333, 'lon': 114.26667}}, {'zip': '441138', 'city': 'Xiangyang', 'state': 'Hubei', 'status': 'RECRUITING', 'country': 'China', 'facility': 'Xiangyang Central Hospital', 'geoPoint': {'lat': 32.0422, 'lon': 112.14479}}, {'zip': '210008', 'city': 'Nanjing', 'state': 'Jiangsu', 'status': 'RECRUITING', 'country': 'China', 'facility': 'The Affiliated Hospital of Nanjing University Medical School', 'geoPoint': {'lat': 32.06167, 'lon': 118.77778}}, {'zip': '330006', 'city': 'Nanchang', 'state': 'Jiangxi', 'status': 'RECRUITING', 'country': 'China', 'facility': 'Jiangxi Maternal and Child Health Hospital', 'geoPoint': {'lat': 28.68396, 'lon': 115.85306}}, {'zip': '130021', 'city': 'Changchun', 'state': 'Jilin', 'status': 'RECRUITING', 'country': 'China', 'facility': 'The First Hospital of Jilin University', 'geoPoint': {'lat': 43.88, 'lon': 125.32278}}, {'zip': '710061', 'city': "Xi'an", 'state': 'Shaanxi', 'status': 'RECRUITING', 'country': 'China', 'facility': 'The First Affiliated Hospital of Xian Jiaotong University', 'geoPoint': {'lat': 34.25833, 'lon': 108.92861}}, {'zip': '250117', 'city': 'Jinan', 'state': 'Shandong', 'status': 'RECRUITING', 'country': 'China', 'facility': 'Cancer Hospital of Shandong First Medical University', 'geoPoint': {'lat': 36.66833, 'lon': 116.99722}}, {'zip': '276001', 'city': 'Linyi', 'state': 'Shandong', 'status': 'RECRUITING', 'country': 'China', 'facility': 'Linyi Cancer Hospital', 'geoPoint': {'lat': 35.06306, 'lon': 118.34278}}, {'zip': '200032', 'city': 'Shanghai', 'state': 'Shanghai Municipality', 'status': 'RECRUITING', 'country': 'China', 'facility': 'Fudan University Shanghai Cancer Center', 'geoPoint': {'lat': 31.22222, 'lon': 121.45806}}, {'zip': '610072', 'city': 'Chengdu', 'state': 'Sichuan', 'status': 'RECRUITING', 'country': 'China', 'facility': "Sichuan Provincial People's Hospital", 'geoPoint': {'lat': 30.66667, 'lon': 104.06667}}, {'zip': '300060', 'city': 'Tianjin', 'state': 'Tianjin Municipality', 'status': 'RECRUITING', 'country': 'China', 'facility': 'Tianjin Medical University Cancer Institute & Hospital', 'geoPoint': {'lat': 39.14222, 'lon': 117.17667}}, {'zip': '310022', 'city': 'Hangzhou', 'state': 'Zhejiang', 'status': 'RECRUITING', 'country': 'China', 'facility': 'Zhejiang Cancer Hospital', 'geoPoint': {'lat': 30.29365, 'lon': 120.16142}}, {'zip': '325015', 'city': 'Wenzhou', 'state': 'Zhejiang', 'status': 'RECRUITING', 'country': 'China', 'facility': 'The First Affiliated Hospital of Wenzhou Medical University', 'geoPoint': {'lat': 27.99942, 'lon': 120.66682}}, {'zip': '100142', 'city': 'Beijing', 'status': 'RECRUITING', 'country': 'China', 'facility': 'Beijing Cancer Hospital', 'geoPoint': {'lat': 39.9075, 'lon': 116.39723}}, {'zip': '350014', 'city': 'Fuzhou', 'status': 'RECRUITING', 'country': 'China', 'facility': 'Fujian Provincial Cancer Hospital', 'geoPoint': {'lat': 26.06139, 'lon': 119.30611}}, {'zip': '42601', 'city': 'Daegu', 'status': 'RECRUITING', 'country': 'South Korea', 'facility': 'Keimyung Univty Dongsan Hospital', 'geoPoint': {'lat': 35.87028, 'lon': 128.59111}}, {'zip': '10408', 'city': 'Goyang', 'status': 'RECRUITING', 'country': 'South Korea', 'facility': 'National Cancer Center', 'geoPoint': {'lat': 36.21689, 'lon': 127.19731}}, {'zip': '13620', 'city': 'Seongnam', 'status': 'RECRUITING', 'country': 'South Korea', 'facility': 'Seoul National University Bundang Hospital', 'geoPoint': {'lat': 35.54127, 'lon': 127.39683}}, {'zip': '02841', 'city': 'Seoul', 'status': 'RECRUITING', 'country': 'South Korea', 'facility': 'Korea University Anam Hospital', 'geoPoint': {'lat': 37.566, 'lon': 126.9784}}, {'zip': '03080', 'city': 'Seoul', 'status': 'RECRUITING', 'country': 'South Korea', 'facility': 'Seoul National University Hospital', 'geoPoint': {'lat': 37.566, 'lon': 126.9784}}, {'zip': '03722', 'city': 'Seoul', 'status': 'RECRUITING', 'country': 'South Korea', 'facility': 'Severance Hospital, Yonsei University Health System', 'geoPoint': {'lat': 37.566, 'lon': 126.9784}}, {'zip': '05505', 'city': 'Seoul', 'status': 'RECRUITING', 'country': 'South Korea', 'facility': 'Asan Medical Center', 'geoPoint': {'lat': 37.566, 'lon': 126.9784}}, {'zip': '06273', 'city': 'Seoul', 'status': 'RECRUITING', 'country': 'South Korea', 'facility': 'Gangnam Severance Hospital, Yonsei University Health System', 'geoPoint': {'lat': 37.566, 'lon': 126.9784}}, {'zip': '06351', 'city': 'Seoul', 'status': 'RECRUITING', 'country': 'South Korea', 'facility': 'Samsung Medical Center', 'geoPoint': {'lat': 37.566, 'lon': 126.9784}}, {'zip': '40447', 'city': 'Taichung', 'status': 'RECRUITING', 'country': 'Taiwan', 'facility': 'China Medical University Hospital', 'geoPoint': {'lat': 24.1469, 'lon': 120.6839}}, {'zip': '40705', 'city': 'Taichung', 'status': 'RECRUITING', 'country': 'Taiwan', 'facility': 'Taichung Veterans General Hospital', 'geoPoint': {'lat': 24.1469, 'lon': 120.6839}}, {'zip': '433004', 'city': 'Taichung', 'status': 'RECRUITING', 'country': 'Taiwan', 'facility': 'Kuang Tien General Hospital', 'geoPoint': {'lat': 24.1469, 'lon': 120.6839}}, {'zip': '70457', 'city': 'Tainan', 'status': 'RECRUITING', 'country': 'Taiwan', 'facility': 'National Cheng Kung University Hospital', 'geoPoint': {'lat': 22.99083, 'lon': 120.21333}}, {'zip': '10449', 'city': 'Taipei', 'status': 'RECRUITING', 'country': 'Taiwan', 'facility': 'MacKay Memorial Hospital_ Taipei Branch', 'geoPoint': {'lat': 25.05306, 'lon': 121.52639}}, {'zip': '11217', 'city': 'Taipei', 'status': 'RECRUITING', 'country': 'Taiwan', 'facility': 'Taipei Veterans General Hospital', 'geoPoint': {'lat': 25.05306, 'lon': 121.52639}}, {'zip': 'BN2 1ES', 'city': 'Brighton', 'status': 'RECRUITING', 'country': 'United Kingdom', 'facility': 'Royal Sussex County Hospital', 'geoPoint': {'lat': 50.82838, 'lon': -0.13947}}, {'zip': 'BS2 8ED', 'city': 'Bristol', 'status': 'RECRUITING', 'country': 'United Kingdom', 'facility': 'Bristol Haematology and Oncology Centre', 'geoPoint': {'lat': 51.45523, 'lon': -2.59665}}, {'zip': 'CB2 0QQ', 'city': 'Cambridge', 'status': 'RECRUITING', 'country': 'United Kingdom', 'facility': "Addenbrooke's Hospital", 'geoPoint': {'lat': 52.2, 'lon': 0.11667}}, {'zip': 'HU165JQ', 'city': 'Cottingham', 'status': 'RECRUITING', 'country': 'United Kingdom', 'facility': 'Castle Hill Hospital', 'geoPoint': {'lat': 52.50243, 'lon': -0.7554}}, {'zip': 'EX2 5DW', 'city': 'Exeter', 'status': 'RECRUITING', 'country': 'United Kingdom', 'facility': 'Royal Devon & Exeter HPT', 'geoPoint': {'lat': 50.7236, 'lon': -3.52751}}, {'zip': 'SA2 8QA', 'city': 'Swansea', 'status': 'RECRUITING', 'country': 'United Kingdom', 'facility': 'Singleton Hospital', 'geoPoint': {'lat': 51.62079, 'lon': -3.94323}}, {'zip': 'TR1 3LJ', 'city': 'Truro', 'status': 'RECRUITING', 'country': 'United Kingdom', 'facility': 'Royal Cornwall Hospital', 'geoPoint': {'lat': 50.26526, 'lon': -5.05436}}], 'centralContacts': [{'name': 'BioNTech clinical trials patient information', 'role': 'CONTACT', 'email': 'patients@biontech.de', 'phone': '+49 6131 9084', 'phoneExt': '0'}], 'overallOfficials': [{'name': 'BioNTech Responsible Person', 'role': 'STUDY_DIRECTOR', 'affiliation': 'BioNTech SE'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'BioNTech SE', 'class': 'INDUSTRY'}, 'collaborators': [{'name': 'DualityBio Inc.', 'class': 'INDUSTRY'}], 'responsibleParty': {'type': 'SPONSOR'}}}}